Did you know? The term "Disease X" refers to a new emerging disease which we currently know nothing about. We don't know when the next Disease X will emerge - but VIDO scientists are preparing! #CanadasCentreforPandemicResearch #VIDOis50

BIOSTAR Inc. was officially incorporated and open for business in 1983. BIOSTAR was VIDO’s first spin-off company designed to assist with marketing technologies and products developed at VIDO. #VIDOis50

Join millions who have switched to Grok.

VIDO’s research focuses on “One Health”. One Health recognizes that the health of people is closely connected to the health of animals and our shared environment. By protecting animals, we can help to protect humans from emerging infectious disease. #VIDOis50

We’re proud of Mina Zhiani, one of our 4th-year students, who presented at #IUIS2025 in Vienna, the world’s largest international immunology meeting. She shared ways to improve vaccination strategies against respiratory diseases like RSV.

In 1993, Dr. Lorne Babiuk became VIDO’s third Director. #VIDOis50

Did you know? VIDO was selected as the Prairie site for the launch of Canada’s new $100 bank note in 2011? #VIDOis50

Did you know? VIDO has generated 4 spin-off companies (BioStar, BioWest, StarBioTech, and PREVENT) #VIDOis50

In 2013 InterVac went “hot” and containment level 3 (CL3) projects began following certification from government regulatory agencies #VIDOis50

📣 We’re hiring a Human Resources Coordinator! A great entry-level role for someone passionate about people, culture & organizational development. Join us & help build a positive, inclusive workplace. Apply here: #WorkatVIDO #WorkWithUs

In 2011, VIDO celebrated the opening of its $140 million containment level 3 facility – the International Vaccine Centre (InterVac) #VIDOis50

VIDO is building a new animal housing facility that will expand our research capacity—housing everything from mosquitoes to ticks to bats🦟🕷️🦇. These vectors are crucial for disease spread, and access to them will help us better prepare for emerging threats. #VIDOis50

VIDO received its first livestock contribution in 1977 from the Alberta Egg and Fowl Marketing Board #VIDOis50

In 1979 VIDO’s first vaccine was licensed for sale by Connaught Laboratories Ltd of Toronto. VICOGEN was the world's first safe, economical, and proven-effective vaccine against bacterial calf scours caused by E.coli. It was a ‘game changer’ for the livestock sector. #VIDOis50

This week, VIDO scientists joined global experts in Vienna for the International Veterinary Immunology Symposium. Our team shared research on:.🐄 HPAI in dairy cows.🧬 Gut loop model for Johne’s disease in calves.💉 Innovations in veterinary vaccine development.#IVIS2025

In 1984, VIDO’s second vaccine ECOLAN RC™ was commercialized as a subunit vaccine against calf scours caused by E. coli, rotavirus and coronavirus. #VIDOis50

New TB research! 🧫 A collab between VIDO & UBC shows the Parkinson’s drug benztropine may help immune cells fight TB. VIDO confirmed it works in infected mice using our CL3 labs. Great example of shared expertise in action. 🔗 #TBResearch #usask #ubc.

In 1983, Dr. Stephen Acres replaced Dr. Chris Bigland as VIDO's second director. #VIDOis50

🎉Congratulations Dr. Vince Bruni-Bossio! Looking forward to working together to grow @usask’s international reputation and global impact.

In 1986, VIDO licensed HEVLAN TC™ - the world's first tissue culture-produced vaccine for hemorrhagic enteritis of turkeys. #VIDOis50

The idea for VIDO was conceived by farmers, agriculturalists and veterinarians and was first requested in a resolution to the Alberta government in 1957. Dr. Chris Bigland, VIDO’s first director, is responsible for our creation. #VIDOis50